Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC

/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab...

Related Keywords

China ,Turkey ,Shanghai ,United States ,Ningbo ,Zhejiang ,Poland ,United Kingdom ,Xuhui ,Xiamen ,Fujian ,Sichuan ,Gansu ,Australia ,Chengdu ,Songjiang ,Jilin ,Georgia ,American ,British ,Chinese ,Jing Huang ,Fosun Pharma ,Wenjie Zhang ,Kalbe Genexine Biologics Kgbio ,Jason Zhu ,Cancer Hospital Chinese Academy Of Medical Sciences ,European Commission ,Bureau Of Medical Administration ,European Medicines Agency ,Cancer Association ,Drug Administration ,Prnewswire Shanghai Henlius Biotech Inc ,Journal Of The American Medical Association ,Journal Of The National Cancer Center ,National Health Commission Of The People ,Cancer Association Sichuan Anti ,Sasia Congress ,National Medical Products Administration ,Henlius Biotech ,Executive Director ,Chief Executive Officer ,Chief Financial Officer ,Cancer Hospital Chinese Academy ,Medical Sciences ,Nature Medicine ,Marketing Authorization Application ,Biologics License Application ,Ningxia Hui Autonomous Region ,Kalbe Genexine Biologics ,North Africa ,National Cancer Center ,Academic Annual Meeting ,Specialized Committee ,Geriatric Tumor Therapy ,Sichuan Anti Cancer Association ,First Academic Annual Meeting ,Anti Cancer Drugs ,Medical Administration ,National Health Commission ,American Medical Association ,British Journal ,Small Cell Lung Cancer ,Non Small Cell Lung Cancer ,Esophageal Cancer ,Colorectal Cancer ,Practice Guidelines ,Immune Checkpoint Inhibitor ,China Guidelines ,Good Manufacturing Practice ,Xuhui Plant ,Songjiang First Plant ,Henlius ,